Tumor-associated fluids, including interstitial, vascular, and lymphatic fluids, are increasingly recognized as active regulators of cancer progression rather than passive transport media within the tumor microenvironment. As an integrative working concept, liquid–cell interactions describe how these fluids regulate biochemical signaling, extracellular vesicle trafficking, metabolite exchange, and force transmission among cancer, stromal, and immune cells. Hydrodynamic forces, chemical gradients, extracellular vesicles (EVs), and damage-associated signals jointly shape proliferation, invasion, metabolic reprogramming, angiogenesis, immune escape, and inflammatory propagation. Perturbations in flow, viscosity, pH, and fluid composition further remodel tissue architecture and reprogram cell states, thereby influencing therapeutic response. Clinically, liquid-phase biomarkers, including circulating cytokines, nucleic acids, EVs, and circulating tumor cells, support early detection, real-time monitoring, and resistance prediction. Therapeutically, strategies that normalize fluid dynamics, modulate soluble signaling networks, or block vesicle trafficking show translational promise and may enhance standard treatments. This review synthesizes recent advances from mechanisms to clinical applications and highlights the liquid phase as a distinct regulatory dimension of the tumor microenvironment with diagnostic and therapeutic relevance.
Alix-PanabièresC, PantelK.Liquid biopsy: from discovery to clinical implementation. Mol Oncol2021;15(6):1617–1621; doi: 10.1002/1878-0261.12997
2.
BaronzioG, SchwartzL, KiselevskyM, et al.Tumor interstitial fluid as modulator of cancer inflammation, thrombosis, immunity and angiogenesis. Anticancer Res2012;32(2):405–414.
3.
BeraK, KiepasA, GodetI, et al.Extracellular fluid viscosity enhances cell migration and cancer dissemination. Nature2022;611(7935):365–373.
4.
BhawalR, ObergAL, ZhangS, et al.Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer. Cancers2020;12(9):2428; doi: 10.3390/cancers12092428
5.
BöckelmannLC, SchumacherU. Targeting tumor interstitial fluid pressure: Will it yield novel successful therapies for solid tumors. Expert Opin Ther Targets2019;23(12):1005–1014.
6.
BoedtkjerE, PedersenSF. The acidic tumor microenvironment as a driver of cancer. Annu Rev Physiol2020;82:103–126.
7.
BoukovalaM, WestphalenCB, ProbstV. Liquid biopsy into the clinics: Current evidence and future perspectives. J Liq Biopsy2024;4:100146.
8.
BullockE, RozyczkoA, ShabbirS, et al.Cancer-associated fibroblast driven paracrine IL-6/STAT3 signaling promotes migration and dissemination in invasive lobular carcinoma. Breast Cancer Res2025;27(1):121.
9.
Campos-CarrilloA, WeitzelJN, SahooP, et al.Circulating tumor DNA as an early cancer detection tool. Pharmacol Ther2020;207:107458; doi: 10.1016/j.pharmthera.2019.107458
10.
CaoloV, DebantM, EndeshN, et al.Shear stress activates ADAM10 sheddase to regulate Notch1 via the Piezo1 force sensor in endothelial cells. Elife2020;9:e50684.
11.
Cecerska-HeryćE, JerzykA, GoszkaM, et al.TGF-β signaling in cancer: Mechanisms of progression and therapeutic targets. Int J Mol Sci2025;26(15):7326.
12.
ChenZ, HanF, DuY, et al.Hypoxic microenvironment in cancer: Molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther2023;8(1):70.
13.
ChunyuC, ZhaoX, YanL, et al.Enhancement effects of extracellular fluid viscosity and matrix stiffness on cancer cell mechanosensing. Acta Mechanica SINICA2023;39(11).
14.
CieślukM, PiktelE, WnorowskaU, et al.Substrate viscosity impairs temozolomide-mediated inhibition of glioblastoma cells’ growth. Biochim Biophys Acta Mol Basis Dis2022;1868(11):166513.
15.
DouX, FuQ, LongQ, et al.PDK4-dependent hypercatabolism and lactate production of senescent cells promotes cancer malignancy. Nat Metab2023;5(11):1887–1910.
16.
EbleJA, NilandS. The extracellular matrix in tumor progression and metastasis. Clin Exp Metastasis2019;36(3):171–198.
17.
ErdoganB, WebbDJ. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochem Soc Trans2017;45(1):229–236.
18.
FerruzziJ, SunM, GkousioudiA, et al.Compressive remodeling alters fluid transport properties of collagen networks - implications for tumor growth. Sci Rep2019;9(1):17151.
19.
FlournoyJ, AshkananiS, ChenY. Mechanical regulation of signal transduction in angiogenesis. Front Cell Dev Biol2022;10:933474.
20.
FukushiA, KimHD, ChangYC, et al.Revisited metabolic control and reprogramming cancers by means of the Warburg effect in tumor cells. Int J Mol Sci2022;23(17):10037.
21.
GeH, TianM, PeiQ, et al.Extracellular Matrix Stiffness: New Areas Affecting Cell Metabolism. Front Oncol2021;11:631991; doi: 10.3389/fonc.2021.631991
22.
GuanA, QuekC. Single-Cell Multi-OMICS: Insights into therapeutic innovations to advance treatment in cancer. Int J Mol Sci2025;26(6):2447.
23.
GujarV, LiH, PaullTT, et al.Unraveling the nexus: Genomic instability and metabolism in cancer. Cell Rep2025;44(4):115540.
24.
HaoY, BakerD, Ten DijkeP. TGF-β-Mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci2019;20(11):2767.
25.
HuQ, ZhuY, MeiJ, et al.Extracellular matrix dynamics in tumor immunoregulation: From tumor microenvironment to immunotherapy. J Hematol Oncol2025;18(1):65.
26.
HuangQ, HuX, HeW, et al.Fluid shear stress and tumor metastasis. Am J Cancer Res2018;8(5):763–777.
27.
IrmerB, ChandrabalanS, MaasL, et al. (2023). Extracellular Vesicles in Liquid Biopsies as Biomarkers for Solid Tumors. Cancers (Basel). 15.
28.
JacobS, DavisAA, GerratanaL, et al.The use of serial circulating tumor DNA to detect resistance alterations in progressive metastatic breast cancer. Clin Cancer Res2021;27(5):1361–1370.
29.
KalluriR, LeBleuVS. The biology, function, and biomedical applications of exosomes. Science2020;367(6478):eaau6977.
30.
KarakousiT, MudiantoT, LundAW. Lymphatic vessels in the age of cancer immunotherapy. Nat Rev Cancer2024;24(6):363–381.
31.
KimHS, NamJS. The multifaceted role of YAP in the tumor microenvironment and its therapeutic implications in cancer. Exp Mol Med2025;57(10):2201–2213.
32.
KimOH, ChoiYW, ParkJH, et al.Fluid shear stress facilitates prostate cancer metastasis through Piezo1-Src-YAP axis. Life Sci2022;308:120936.
33.
KureshiCT, DouganSK. Cytokines in cancer. Cancer Cell2025;43(1):15–35.
34.
LandegrenU, HammondM.Cancer diagnostics based on plasma protein biomarkers: hard times but great expectations. Mol Oncol2021;15(6):1715–1726; doi: 10.1002/1878-0261.12809
35.
LeoneP, MalerbaE, SuscaN, et al.Endothelial cells in tumor microenvironment: Insights and perspectives. Front Immunol2024;15:1367875.
36.
LiangY, ShaoY, GuW. Role of interleukin-6 in resistance to tumor therapy. Discov Oncol2025;16(1):1791.
37.
LibuttiSK, TamarkinL, NilubolN. Targeting the invincible barrier for drug delivery in solid cancers: Interstitial fluid pressure. Oncotarget2018;9(87):35723–35725.
38.
LinD, ShenL, LuoM, et al.Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther2021;6:404.
39.
LiuX, ZhangJ, YiT, et al.Decoding tumor angiogenesis: Pathways, mechanisms, and future directions in anti-cancer strategies. Biomark Res2025;13(1):62.
40.
LiuY, WangY, GemingnuerA, et al.Tumor-responsive nanomedicines for cancer therapy: Design principles and therapeutic advances. Biomed Mater2025;20(5).
41.
LiuZL, ChenHH, ZhengLL, et al.Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther2023;8(1):198.
42.
LuJ, ZhaoZ, PanL, et al.Hyaluronidase: Structure, mechanism of action, diseases and therapeutic targets. Mol Biomed2025;6(1):50.
43.
RoerdenM, SprangerS. Cancer immune evasion, immunoediting and intratumour heterogeneity. Nat Rev Immunol2025;25(5):353–369.
44.
MaF, LiuX, ZhangY, et al.Tumor extracellular vesicle-derived PD-L1 promotes T cell senescence through lipid metabolism reprogramming. Sci Transl Med2025;17(785):eadm7269.
45.
MaZ, WeiK, YangF, et al.Tumor-derived exosomal miR-3157-3p promotes angiogenesis, vascular permeability and metastasis by targeting TIMP/KLF2 in non-small cell lung cancer. Cell Death Dis2021;12(9):840.
46.
MunsonJM, ShiehAC. Interstitial fluid flow in cancer: Implications for disease progression and treatment. Cancer Manag Res2014;6:317–328.
47.
OzgaAJ, ChowMT, LusterAD. Chemokines and the immune response to cancer. Immunity2021;54(5):859–874.
48.
ParumsDV.A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitoring Treatment Response. Med Sci Monit2025;31:e949300; doi: 10.12659/MSM.949300
49.
PaskehM, EntezariM, MirzaeiS, et al.Emerging role of exosomes in cancer progression and tumor microenvironment remodeling. J Hematol Oncol2022;15(1):83.
50.
QuP, ZhangH. The dual role of Piezo1 in tumor cells and immune cells: A new target for cancer therapy. Front Immunol2025;16:1635388.
51.
ShahS, D’SouzaGGM. Modeling tumor microenvironment complexity in vitro: Spheroids as physiologically relevant tumor models and strategies for their analysis. Cells2025;14(10):732.
52.
SwartzMA, LundAW. Lymphatic and interstitial flow in the tumour microenvironment: Linking mechanobiology with immunity. Nat Rev Cancer2012;12(3):210–219.
53.
ThuyaWL, CaoY, HoPC, et al.Insights into IL-6/JAK/STAT3 signaling in the tumor microenvironment: Implications for cancer therapy. Cytokine Growth Factor Rev2025;85:26–42.
54.
VarkeyJ, NicolaidesT.Tumor-Educated Platelets: A Review of Current and Potential Applications in Solid Tumors. Cureus2021;13(11):e19189; doi: 10.7759/cureus.19189
55.
VasilakiD, BakopoulouA, TsouknidasA, et al.Biophysical interactions between components of the tumor microenvironment promote metastasis. Biophys Rev2021;13(3):339–357.
56.
WagnerM, WiigH. Tumor interstitial fluid formation, characterization, and clinical implications. Front Oncol2015;5:115.
57.
WangY, ZhangH, LiH, et al.Application of tumor-educated platelets as new fluid biopsy markers in various tumors. Clin Transl Oncol2023;25(1):114–125; doi: 10.1007/s12094-022-02937-1
58.
WrightS, PujaK, VíctorF, et al.Transplantation of gasdermin pores by extracellular vesicles propagates pyroptosis to bystander cells. Cell2025;188(2):280–291.e17.
59.
WuC, WeisSM, ChereshDA. Upregulation of fibronectin and its integrin receptors - an adaptation to isolation stress that facilitates tumor initiation. J Cell Sci2023;136(20):jcs261483.
60.
WuD, DongS, ZhouW. Insulin—like growth factor in cancer: New perspectives (Review). Mol Med Rep2025;32(2):209.
61.
XiaoY, YuD. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther2021;221:107753.
62.
YuD, LiY, WangM, et al.Exosomes as a new frontier of cancer liquid biopsy. Mol. Cancer2022;21:56.
63.
ZanotelliMR, Reinhart-KingCA. Mechanical forces in tumor angiogenesis. Adv Exp Med Biol2018;1092:91–112.
64.
ZhangC, QiY, LiX, et al.The role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients. Biomed Pharmacother2015;69:242–248.
65.
ZhangW, JiangX, ZouY, et al.Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma. Front Pharmacol2023;14:1092767.
66.
ZhangY, FuQ, SunW, et al.Mechanical forces in the tumor microenvironment: Roles, pathways, and therapeutic approaches. J Transl Med2025;23(1):313.
67.
ZhaoT, HuangY, ZhuJ, et al.Extracellular matrix signaling cues: Biological functions, diseases, and therapeutic targets. MedComm (2020)2025;6(8):e70281.
68.
ZhaoY, ShenM, WuL, et al.Stromal cells in the tumor microenvironment: Accomplices of tumor progression. Cell Death Dis2023;14(9):587.
69.
ZhouY, ZhangY, GongH, et al.The role of exosomes and their applications in cancer. Int J Mol Sci2021;22(22):12204.
